" class="no-js "lang="en-US"> Novo Nordisk Archives - Medtech Alert
Friday, March 29, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Debiopharm Extends Their DNA Damage Repair Footprint With New Oncology Pipeline Entry

Debiopharm, an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer […]

Echosens and Novo Nordisk Announce Partnership to Increase Awareness and Advance Early Diagnosis of NASH

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global […]

Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo […]

Novo Nordisk Receives Fda Approval of Higher-dose Ozempic® 2 Mg Providing Increased Glycemic Control for Adults With Type 2 Diabetes

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a […]

Novo Nordisk Expands Research Collaboration in Novel Delivery Technologies for Biologic Medicines

Novo Nordisk today announced the expansion of its existing research collaboration in oral drug delivery […]

Novo Nordisk to Acquire Dicerna Pharmaceuticals Including the RNAi Research Technology Platform

Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more